SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties

Nature

Volumn 503, Issue 7474, 2013, Pages 72-77

  Han, Kihoon ^a,b   Holder, J Lloyd ^a,b   Schaaf, Christian P ^a,b   Lu, Hui ^a,b   Chen, Hongmei ^a,b   Kang, Hyojin ^a,b,c   Tang, Jianrong ^a,b   Wu, Zhenyu ^a,b   Hao, Shuang ^a,b   Cheung, Sau Wai ^a   Yu, Peng ^a,b   Sun, Hao ^a,b   Breman, Amy M ^a   Patel, Ankita ^a   Lu, Hui Chen ^a,b   Zoghbi, Huda Y ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c Korea Institute of Science and Technology Information (KISTI)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN RELATED PROTEIN 2-3 COMPLEX; F ACTIN; SCAFFOLD PROTEIN; SHANK3 PROTEIN; UNCLASSIFIED DRUG; VALPROIC ACID;

BRAIN; DRUG; LITHIUM; PHENOTYPE;

ACTIN FILAMENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT THERAPY; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CHROMOSOME 22Q; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; GENE DUPLICATION; GENE INTERACTION; GENE OVEREXPRESSION; HUMAN; HYPERACTIVITY; HYPERKINESIA; HYPERPHAGIA; IMMOBILITY; KLEPTOMANIA; LOCOMOTION; MOUSE; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; SEIZURE; SOCIAL INTERACTION; TRANSGENIC MOUSE;

MUS MUSCULUS;

EID: 84887404798     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature12630     Document Type: Article

References (55)

1. Südhof, T. C. Neuroligins and neurexins link synaptic function to cognitive disease. Nature 455, 903-911 (2008).
2. Zoghbi, H. Y. Postnatal neurodevelopmental disorders: meeting at the synapse? Science 302, 826-830 (2003).
3. Bourgeron, T. A synaptic trek to autism. Curr. Opin.Neurobiol. 19, 231-234 (2009).
4. Ting, J. T., Peca, J. & Feng, G. Functional consequences of mutations in postsynaptic scaffolding proteins and relevance to psychiatric disorders. Annu. Rev. Neurosci. 35, 49-71 (2012).
5. Sheng, M. & Kim, E. The Shank family of scaffold proteins. J. Cell Sci. 113, 1851-1856 (2000).
6. Sato, D. et al. SHANK1 Deletions in Males with Autism Spectrum Disorder. Am. J. Hum. Genet. 90, 879-887 (2012).
7. Berkel, S. et al. Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation. Nature Genet. 42, 489-491 (2010).
8. Grabrucker, A. M., Schmeisser, M. J., Schoen, M. & Boeckers, T. M. Postsynaptic ProSAP/Shank scaffolds in the cross-hair of synaptopathies. Trends Cell Biol. 21, 594-603 (2011).
9. Durand, C. M. et al.Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autismspectrum disorders. Nature Genet. 39, 25-27 (2007).
10. Moessner, R. et al. Contribution of SHANK3 mutations to autism spectrum disorder. Am. J. Hum. Genet. 81, 1289-1297 (2007).
11. Gauthier, J. et al. Novel de novo SHANK3 mutation in autistic patients. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 150B, 421-424 (2009).
12. Gauthier, J. et al. De novomutations in the gene encoding the synaptic scaffolding protein SHANK3 in patients ascertained for schizophrenia. Proc. Natl Acad. Sci. USA 107, 7863-7868 (2010).
13. Bonaglia, M. C. et al. Disruption of the ProSAP2 gene in a t(12;22)(q24.1;q13.3) is associated with the 22q13.3 deletion syndrome. Am. J. Hum. Genet. 69, 261-268 (2001).
14. Bonaglia, M. C. et al. Identification of a recurrent breakpoint within the SHANK3 gene in the 22q13.3 deletion syndrome. J. Med. Genet. 43, 822-828 (2006).
15. Bozdagi, O. et al. Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication. Mol. Autism 1, 15 (2010).
16. Peça, J. et al. Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 472, 437-442 (2011).
17. Wang, X. et al.Synaptic dysfunction and abnormal behaviors in mice lackingmajor isoforms of Shank3. Hum. Mol. Genet. 20, 3093-3108 (2011).
18. Failla, P.et al. Schizophrenia in a patient with subtelomeric duplication of chromosome 22q. Clin. Genet. 71, 599-601 (2007).
19. Shaltiel, G. et al. Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Mol. Psychiatry 13, 858-872 (2008).
20. Leibenluft, E. & Rich, B. A. Pediatric bipolar disorder. Annu. Rev. Clin. Psychol. 4, 163-187 (2008).
21. Martinowich, K., Schloesser, R. J. & Manji, H. K. Bipolar disorder: from genes to behavior pathways. J. Clin. Invest. 119, 726-736 (2009).
22. Perry, W., Minassian, A., Feifel, D. & Braff, D. L. Sensorimotor gating deficits in bipolar disorder patients with acute psychoticmania. Biol. Psychiatry 50, 418-424 (2001).
23. Belmaker, R. H. Bipolar disorder. N. Engl. J. Med. 351, 476-486 (2004).
24. McCormick, D. A. & Contreras, D. On the cellular and network bases of epileptic seizures. Annu. Rev. Physiol. 63, 815-846 (2001).
25. Sakai, Y. et al. Protein interactome reveals convergingmolecular pathways among autism disorders. Sci. Transl. Med. 3, 86ra49 (2011).
26. Collins, M. O. et al. Molecular characterization and comparison of the components and multiprotein complexes in the postsynaptic proteome. J. Neurochem. 97 (Suppl 1), 16-23 (2006).
27. Bayés, A. et al. Characterization of the proteome, diseases and evolution of the human postsynaptic density. Nature Neurosci. 14, 19-21 (2011).
28. Campellone, K. G. & Welch, M. D. A nucleator arms race: cellular control of actin assembly. Nature Rev. Mol. Cell Biol. 11, 237-251 (2010).
29. Proepper, C. et al. Abelson interacting protein 1 (Abi-1) is essential for dendrite morphogenesis and synapse formation. EMBO J. 26, 1397-1409 (2007).
30. Naisbitt, S. et al.Shank, a novel family ofpostsynaptic density proteins that binds to the NMDA receptor/PSD-95/GKAP complex and cortactin. Neuron 23, 569-582 (1999).
31. Sheng, M. & Kim, E. The postsynaptic organization of synapses. Cold Spring Harb. Perspect. Biol. (http://dx.doi.org/10.1101/cshperspect.a005678) (2011).
32. Giesemann, T. et al. Complex formation between the postsynaptic scaffolding protein gephyrin, profilin, and Mena: a possible link to the microfilament system. J. Neurosci. 23, 8330-8339 (2003).
33. Neuhoff, H. et al. The actin-binding protein profilin I is localized at synaptic sites in an activity-regulated manner. Eur. J. Neurosci. 21, 15-25 (2005).
34. Ackermann, M. & Matus, A. Activity-induced targeting of profilin and stabilization of dendritic spine morphology. Nature Neurosci. 6, 1194-1200 (2003).
35. Jope, R. S. Anti-bipolar therapy: mechanism of action of lithium. Mol. Psychiatry 4, 117-128 (1999).
36. Rosenberg, G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell. Mol. Life Sci. 64, 2090-2103 (2007).
37. Ramocki, M. B. & Zoghbi, H. Y. Failure of neuronal homeostasis results in common neuropsychiatric phenotypes. Nature 455, 912-918 (2008).
38. Toro, R. et al. Key role for gene dosage and synaptic homeostasis in autism spectrum disorders. Trends Genet. 26, 363-372 (2010).
39. Gitlin, M. Treatment-resistant bipolar disorder. Mol. Psychiatry 11, 227-240 (2006).
40. Dunner, D. L. & Fieve, R. R. Clinical factors in lithiumcarbonate prophylaxis failure. Arch. Gen. Psychiatry 30, 229-233 (1974).
41. Gould, T. D. & Manji, H. K. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30, 1223-1237 (2005).
42. Maglóczky, Z. & Freund, T. F. Impaired and repaired inhibitory circuits in the epileptic human hippocampus. Trends Neurosci. 28, 334-340 (2005).
43. Mar?́n, O. Interneuron dysfunction in psychiatric disorders. Nature Rev. Neurosci. 13, 107-120 (2012).
44. Benes, F. M. et al. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc. Natl Acad. Sci. USA 104, 10164-10169 (2007).
45. Schloesser, R. J., Martinowich, K. & Manji, H. K. Mood-stabilizing drugs: mechanisms of action. Trends Neurosci. 35, 36-46 (2012).
46. Warming, S., Costantino, N., Court, D. L., Jenkins, N. A.&Copeland, N. G. Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res. 33, e36 (2005).
47. Choi, J. et al. Regulation of dendritic spine morphogenesis by insulin receptor substrate 53, a downstream effector of Rac1 and Cdc42 small GTPases. J. Neurosci. 25, 869-879 (2005).
48. Han, K. et al. Regulated RalBP1 binding to RalA and PSD-95 controls AMPA receptor endocytosis and LTD. PLoS Biol. 7, e1000187 (2009).
49. Chao, H. T. et al. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 468, 263-269 (2010).
50. Roberson, E. D. et al. Amyloid-b/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci. 31, 700-711 (2011).
51. Lu, H., Lim, B. & Poo, M. M. Cocaine exposure in utero alters synaptic plasticity in the medial prefrontal cortex of postnatal rats. J. Neurosci. 29, 12664-12674 (2009).
52. Shannon, P.et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498-2504 (2003).
53. Dennis, G. et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 4, P3 (2003).
54. Huang D. W., Sherman B. T.& Lempicki R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols 4, 44-57 (2009).
55. Boone, P.M. et al. Detection of clinically relevant exonic copy-number changes by array CGH. Hum. Mutat. 31, 1326-1342 (2010).